Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Stem cell therapy to treat heart ischaemia : implications for diabetes cardiovascular complications. / Ali Qayyum, Abbas; Mathiasen, Anders Bruun; Kastrup, Jens.

In: Current Diabetes Reports, Vol. 14, 554, 12.2014, p. 1-8.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Ali Qayyum, A, Mathiasen, AB & Kastrup, J 2014, 'Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications', Current Diabetes Reports, vol. 14, 554, pp. 1-8. https://doi.org/10.1007/s11892-014-0554-5

APA

Ali Qayyum, A., Mathiasen, A. B., & Kastrup, J. (2014). Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications. Current Diabetes Reports, 14, 1-8. [554]. https://doi.org/10.1007/s11892-014-0554-5

Vancouver

Ali Qayyum A, Mathiasen AB, Kastrup J. Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications. Current Diabetes Reports. 2014 Dec;14:1-8. 554. https://doi.org/10.1007/s11892-014-0554-5

Author

Ali Qayyum, Abbas ; Mathiasen, Anders Bruun ; Kastrup, Jens. / Stem cell therapy to treat heart ischaemia : implications for diabetes cardiovascular complications. In: Current Diabetes Reports. 2014 ; Vol. 14. pp. 1-8.

Bibtex

@article{90790ad599c24af8a5a797ffdce9c642,
title = "Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications",
abstract = "Diabetes mellitus is a well-known risk factor for coronary artery disease (CAD), which can lead to acute myocardial infarction, chronic myocardial ischaemia and heart failure. Despite the advantages in medical treatment, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), morbidity and mortality is still high in patients with CAD. Along with PCI and CABG or in patients without options for revascularization, stem cell regenerative therapy in controlled trials is a possibility. Stem cells are believed to exert their actions by angiogenesis and regeneration of cardiomyocytes. Recently published clinical trials and meta-analysis of stem cell studies have shown encouraging results with increased left ventricle ejection fraction and reduced symptoms in patients with CAD and heart failure. There is some evidence of mesenchymal stem cell being more effective compared to other cell types and cell therapy may be more effective in patients with known diabetes mellitus. However, further investigations are warranted.",
author = "{Ali Qayyum}, Abbas and Mathiasen, {Anders Bruun} and Jens Kastrup",
year = "2014",
month = dec,
doi = "10.1007/s11892-014-0554-5",
language = "English",
volume = "14",
pages = "1--8",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Springer Healthcare",

}

RIS

TY - JOUR

T1 - Stem cell therapy to treat heart ischaemia

T2 - implications for diabetes cardiovascular complications

AU - Ali Qayyum, Abbas

AU - Mathiasen, Anders Bruun

AU - Kastrup, Jens

PY - 2014/12

Y1 - 2014/12

N2 - Diabetes mellitus is a well-known risk factor for coronary artery disease (CAD), which can lead to acute myocardial infarction, chronic myocardial ischaemia and heart failure. Despite the advantages in medical treatment, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), morbidity and mortality is still high in patients with CAD. Along with PCI and CABG or in patients without options for revascularization, stem cell regenerative therapy in controlled trials is a possibility. Stem cells are believed to exert their actions by angiogenesis and regeneration of cardiomyocytes. Recently published clinical trials and meta-analysis of stem cell studies have shown encouraging results with increased left ventricle ejection fraction and reduced symptoms in patients with CAD and heart failure. There is some evidence of mesenchymal stem cell being more effective compared to other cell types and cell therapy may be more effective in patients with known diabetes mellitus. However, further investigations are warranted.

AB - Diabetes mellitus is a well-known risk factor for coronary artery disease (CAD), which can lead to acute myocardial infarction, chronic myocardial ischaemia and heart failure. Despite the advantages in medical treatment, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), morbidity and mortality is still high in patients with CAD. Along with PCI and CABG or in patients without options for revascularization, stem cell regenerative therapy in controlled trials is a possibility. Stem cells are believed to exert their actions by angiogenesis and regeneration of cardiomyocytes. Recently published clinical trials and meta-analysis of stem cell studies have shown encouraging results with increased left ventricle ejection fraction and reduced symptoms in patients with CAD and heart failure. There is some evidence of mesenchymal stem cell being more effective compared to other cell types and cell therapy may be more effective in patients with known diabetes mellitus. However, further investigations are warranted.

U2 - 10.1007/s11892-014-0554-5

DO - 10.1007/s11892-014-0554-5

M3 - Journal article

C2 - 25344789

VL - 14

SP - 1

EP - 8

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

M1 - 554

ER -

ID: 135544010